Evidence map›Paper›PMID 41697969›Full record

ArticleJournal of the National Cancer Institute2026

CRC-SPIN version 3.0: an updated policy model for colorectal cancer screening that includes the serrated pathway.

Carolyn M Rutter, Christopher E Maerzluft, Laura Matrajt, Pedro Nascimento de Lima, Rachel B Issaka, Tracey L Marsh

Abstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Carolyn M RutterHutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Center, Seattle, WA, United States.ORCID 0000-0002-4396-8594
Christopher E MaerzluftHutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Center, Seattle, WA, United States.ORCID 0000-0002-6027-0833
Laura MatrajtVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.ORCID 0000-0003-4495-7245
Pedro Nascimento de LimaDepartment of Engineering and Applied Sciences, RAND Corporation, Arlington, VA, United States.ORCID 0000-0001-9057-198X
Rachel B IssakaHutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Center, Seattle, WA, United States.ORCID 0000-0002-9691-1655
Tracey L MarshDivision of Public Health Sciences, Biostatistics Program, Fred Hutchinson Cancer Center, Seattle, WA, United States.ORCID 0000-0002-6865-5092

Funding

Cancer Intervention and Surveillance Modeling Network R01-MD017599Computational resources were made possible S10-OD-020069Computational resources were made possible S10-OD-028685National Cancer Institute of the National Institutes of Health U01-CA253913National Cancer Institute of the NIHNational Institute of Minority Health and Health Disparities of the National Institutes of Health K08CA241296
6 · The paper itself

Abstract

backgroundMicrosimulation models use empirical evidence about cancer epidemiology and screening test performance to predict the long-term effectiveness of screening regimens and are essential for developing cancer screening guidelines. Colorectal cancer (CRC) provides a clear example. CRC arises through 2 pathways, the adenoma-carcinoma pathway and the serrated pathway. Sessile serrated lesions (SSLs) are the primary serrated precursor lesion. SSLs are more difficult to detect and remove than adenomas.

methodsWe describe version 3.0 of the Colorectal Cancer Simulated Population model for Incidence and Natural history, which adds new information about the serrated pathway and CRC risk in adults younger than 50 years, then estimate the effectiveness of decennial colonoscopy from 45 to 75 years old. The model was calibrated using a Bayesian approach to estimate 95% credible intervals (CIs) that reflect uncertainty in predictions.

resultsThe model validated well to studies of the effect of 1-time screening and outcomes from surveillance colonoscopy. In the absence of screening, SSLs accounted for 10.6% (95% CI = 3.3 - 21.6) of CRC, increasing to 23.5% (95% CI = 7.7% - 46.0%) with screening because of selective removal of adenomas. Screening was predicted to prevent 93.9% (95% CI = 92.0% - 94.3%) of CRC and 95.3% (95% CI = 93.8% - 96.5%) of CRC mortality.

conclusionsAlthough SSLs are less common than adenomas, they likely make up a large fraction of CRC that arises in people who participate in screening. This points to the importance of improving the ability to detect SSLs, especially large SSLs, at colonoscopy.

Indexed as

ColonoscopyColorectal NeoplasmsEarly Detection of CancerMass ScreeningPrecancerous ConditionsAdenomaAgedColonic PolypsComputer SimulationEpidemiological ModelsFemaleHealth PolicyHumansIncidenceMaleMiddle Aged

Identifiers

PMID41697969
PMCPMC13339097

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.